Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

IMPORTANCE: The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and th...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA Oncol
Hoofdauteurs: Abida, Wassim, Cheng, Michael L., Armenia, Joshua, Middha, Sumit, Autio, Karen A., Vargas, Hebert Alberto, Rathkopf, Dana, Morris, Michael J., Danila, Daniel C., Slovin, Susan F., Carbone, Emily, Barnett, Ethan S., Hullings, Melanie, Hechtman, Jaclyn F., Zehir, Ahmet, Shia, Jinru, Jonsson, Philip, Stadler, Zsofia K., Srinivasan, Preethi, Laudone, Vincent P., Reuter, Victor, Wolchok, Jedd D., Socci, Nicholas D., Taylor, Barry S., Berger, Michael F., Kantoff, Philip W., Sawyers, Charles L., Schultz, Nikolaus, Solit, David B., Gopalan, Anuradha, Scher, Howard I.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2018
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459218/
https://ncbi.nlm.nih.gov/pubmed/30589920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5801
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items